Keyphrases
Bevacizumab
100%
Recurrent Glioblastoma
66%
Irinotecan
57%
Overall Survival
48%
Frontotemporal Dementia
37%
Glioma Patients
33%
Cerebrospinal Fluid
33%
CHMP2B
33%
Prognostic Model
27%
Progression-free Survival
26%
Combination Therapy
25%
Ubiquitin
25%
Non-responders
24%
Predictive Biomarker
24%
Multivariate Analysis
20%
Neurodegenerative Diseases
18%
Lomustine
16%
Grade III Gliomas
16%
Epid
16%
Lysosomal Proteins
16%
REEP1
16%
Performance Status
16%
Neurofilament Light (NF-L)
16%
Endolysosomal
16%
WHO Grade 3
16%
Hereditary Spastic Paraplegia
16%
Angiotensinogen
16%
Transcriptional Changes
16%
Protein Concentration
16%
HLA Class II
16%
Prognostic Biomarker
16%
Peripheral Neuropathy
16%
Predictive Prognostics
14%
Necrosis
11%
Prognostic Score
10%
Patient Cohort
9%
Predictive Marker
8%
Best Response
8%
Prognostic Factors
8%
Tumor Tissue
8%
Mutation Carriers
7%
SPG31
6%
Compression Neuropathy
6%
Tumor
6%
Corticosteroid Use
6%
Differentially Expressed
6%
Gene Expression Changes
6%
Asymptomatic Carriers
6%
Clinical Practice
5%
Biomarker Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
66%
Glioblastoma
50%
Biological Marker
45%
Irinotecan
40%
Overall Survival
31%
Degenerative Disease
25%
Frontotemporal Dementia
21%
Lomustine
16%
Ubiquitin
16%
Blood-Brain Barrier
16%
Serum Albumin
16%
Angiotensinogen
16%
Progression Free Survival
10%
Combination Therapy
9%
Cross-Sectional Study
8%
Disease Marker
8%
Disease
7%
Protein P53
5%
Neuroscience
Bevacizumab
50%
Frontotemporal Dementia
37%
Ubiquitin
25%
Neurodegenerative Disorder
18%
Angiotensinogen
16%
Hereditary Spastic Paraplegia
16%
Irinotecan
16%
Neurofilament
16%
Peripheral Neuropathy
16%
Gene Expression
13%
Peripheral Neuropathy
8%
Peripheral Nerve
8%
